Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation

Abstract

Background: There is evidence suggesting that most thromboembolic complications could be prevented with adequate pharmacological anticoagulation. We estimated the direct health care costs of anticoagulant treatment with oral vitamin K antagonists in patients diagnosed with non-valvular atrial fibrillation. Methods. This observational study examined the clinical records of patients diagnosed with non-valvular atrial fibrillation who received anticoagulant treatment with oral vitamin K antagonists. Data from clinical records were used in the study: international normalized ratio, number of monitoring visits, type of anticoagulant, hospital admissions from complications, and concomitant medication. Drug cost was calculated based on the official Spanish Ministry of Health price list. Monitoring expenses were included the cost of the medical supplies used in the procedures. Hospitalization costs were calculated using the Diagnosis Related Group price for each case. Hospital visits costs were calculated by one of four different scenarios, using either the invoice rates for the regional health care authority or cost per visit as established by analytical accounting methods. Results: We collected data from 1,257 patients diagnosed with non-valvular atrial fibrillation who were receiving oral anticoagulant therapy. Depending on the scheme used, the direct health care costs for these patients ranged from 423,695 - 1,436,038 per annum. The average cost per patient varied between 392 - 1,341, depending on the approach used. Patients with international normalized ratio values within the therapeutic range on 25% of their visits represented an average cost between 441.70 - 1,592. Those within the therapeutic range on 25%-50% of visits had associated costs of 512.37 - 1,703.91. When international normalized ratio values were within the therapeutic range on 50% - 75% of the visits, the costs ranged between 400.80- 1,375.74. The average cost was 305.23 - 1,049.84 when the values were within the therapeutic range for over 75% of visits. Conclusions: Most direct health care costs associated with the sampled patients arise from the specialist-care monitoring required for the treatment. Good monitoring is inversely related to direct health care costs. © 2014 Hidalgo-Vega et al.; licensee BioMed Central Ltd.